Shares of Abcam Plc (LON:ABC) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as GBX 1,153 ($15.64) and last traded at GBX 1,132 ($15.35), with a volume of 713792 shares traded. The stock had previously closed at GBX 1,132 ($15.35).

Several analysts recently weighed in on ABC shares. Numis Securities raised their target price on shares of Abcam from GBX 1,116 ($15.13) to GBX 1,200 ($16.27) and gave the company an “add” rating in a report on Tuesday, September 12th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 1,020 ($13.83) target price on shares of Abcam in a report on Wednesday, November 29th. JPMorgan Chase & Co. raised their target price on shares of Abcam from GBX 864 ($11.72) to GBX 946 ($12.83) and gave the company a “neutral” rating in a report on Monday, September 18th. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 1,240 ($16.82) price objective on shares of Abcam in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 996 ($13.51).

The company has a market capitalization of $2,330.00 and a PE ratio of 5,385.71.

COPYRIGHT VIOLATION NOTICE: “Abcam (ABC) Hits New 52-Week High at $1,153.00” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at

Abcam Company Profile

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with's FREE daily email newsletter.